New York, NY -- (SBWIRE) -- 05/22/2013 -- Growing Stock Report expands its NASDAQ Gainers Weekly Watch List adding Amgen Inc. (NASDAQ:AMGN), Warner Chilcott plc (NASDAQ:WCRX) and BioMarin Pharmaceutical Inc. (NASDAQ:BMRN).

Wilmington, DE -- (SBWIRE) -- 05/21/2013 -- Equity Profile Report expands its NASDAQ Gainers Weekly Watch List adding Amgen Inc. (NASDAQ:AMGN) and BioMarin Pharmaceutical Inc. (NASDAQ:BMRN).

Austin, TX -- (SBWIRE) -- 05/21/2013 -- Jackpotpennystocks.com, an investor research portal specializing in several sectors including biotech and healthcare and tech stocks on the U.S. market, issues news updates on the following stock.

New York, May 21st (TradersHuddle.com) - Amgen Inc. (NASDAQ:AMGN) ended the trading session at $102.18, near its 50 day moving average set at $103.39. Amgen's price action placed the stock below this important level, which makes it difficult to be bou. Read More --

New York, May 20th (TradersHuddle.com) - The NASDAQ 100 Index is flat trading at 0, which represents 0% versus its previous close. The index is mixed for the session with slightly less than 50% of its components trading higher.

First Solar ( TradersHuddle.com

New York, May 20th (TradersHuddle.com) - Amgen Inc. (NASDAQ:AMGN) closed the trading day at $105.63, near its 50 day moving average that is set at $103.20. Amgen's price action is just above this important support level, providing a trading opportunit. Read More --

New York, May 16th (TradersHuddle.com) - Shares of Amgen Inc. (NASDAQ:AMGN) closed the trading session at $107.42 with its price action in a very tight range, given that calculated support is set at $103.85 and the calculated resistance is set at $109.56. Read More --

New York, May 14th (TradersHuddle.com) - Shares of Amgen Inc. (NASDAQ:AMGN) are trading very close to calculated support at $103.85 with price action closing at just $106.89 and placing the stock near levels where traders will start paying attentio. Read More --

New York, May 13th (TradersHuddle.com) - Amgen Inc. (NASDAQ:AMGN) closed the trading day at $106.72, near its 50 day moving average that is set at $101.8461. Amgen's price action is just above this important support level, providing a trading opportun. Read More --

Bridgewater, MA -- (SBWIRE) -- 05/09/2013 -- The online StockConsultant latest screen has found a biotechnology medicines company Amgen, Inc. (NASDAQ:AMGN) stock with a 75% bullish overall report and very good upside trade quality.

New York, NY -- (SBWIRE) -- 05/08/2013 -- Growing Stock Report expands its NASDAQ Decliners Weekly Watch List adding Synta Pharmaceuticals Corp. (NASDAQ:SNTA), Perrigo Co. (NASDAQ:PRGO), and Amgen Inc. (NASDAQ:AMGN).

New York, May 8th (TradersHuddle.com) - Amgen Inc. (NASDAQ:AMGN) closed the trading day at $104.46, near its 50 day moving average that is set at $100.96. Amgen's price action is just above this important support level, providing a trading opportunity. Read More --

Wilmington, DE -- (SBWIRE) -- 05/07/2013 -- Equity Profile Report expands its NASDAQ Decliners Weekly Watch List adding Synta Pharmaceuticals Corp. (NASDAQ:SNTA), Perrigo Co. (NASDAQ:PRGO), and Amgen Inc. (NASDAQ:AMGN).

New York, NY -- (SBWIRE) -- 05/07/2013 -- Growing Stock Report expands its NASDAQ Decliners Weekly Watch List adding Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Amgen Inc. (NASDAQ:AMGN).

New York, May 7th (TradersHuddle.com) - Shares of Amgen Inc. (NASDAQ:AMGN) finished near calculated support at $103.85.

The biotechnology company closed at $104.83 leaving shares at a level that will spark interest by traders wanting to start or. Read More --

Wilmington, DE -- (SBWIRE) -- 05/06/2013 -- Equity Profile Report expands its NASDAQ Decliners Weekly Watch List adding Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Amgen Inc. (NASDAQ:AMGN).

Some of the most exciting developments in the last fifty years have been in the biotechnology industry - which has also meant the emergence of some of the best investments for 2013.

Just look at the progress biotech has made in medicine.

Using advanced technology and research, scientists in the life sciences industry are working on cures for diseases that have plagued mankind for decades. In a relatively short period of time, biotechnology has produced medications that have pushed many forms of cancer to the brink of defeat. HIV infection went from a death sentence to a manageable - and almost cured - condition, in just a few decades.

Biotech share prices have reflected these successes.

As Barron's pointed out last week, biotech stocks have soared 111% over the past couple years, about three times better than healthcare stocks.

And early investors in biotech have seen astronomical gains over the past four to five years.

Regeneron Pharmaceuticals Inc. (Nasdaq: REGN) has soared from less than $5 a share back in 2005 to more than $240 a share today as its drugs have been used to battle ophthalmological disease and several forms of cancer. Incyte Corp. (Nasdaq: INCY) has seen its stock price rise from $2 a share just four years ago to more than $20 today. Early investors in industry leader Amgen Inc. (Nasdaq: AMGN) have seen gains of almost 100 times their initial investment.

But those gains are far from over.

In fact, right now just may be the best time in history to be an investor in the biotechnology sector.

To continue reading, please click here…

New York, NY -- (SBWIRE) -- 05/02/2013 -- Vringo, Inc.(NASDAQ:VRNG), together with its subsidiaries, engages in the innovation, acquisition, licensing, and protection of intellectual property worldwide. Its intellectual property portfolio consists of approximately 500 patents and patent applications covering telecom infrastructure, Internet search, and mobile technologies. Vringo, Inc. moved 3.90 percent higher, at $2.93 and traded between $2.78 and $3.14 after opening the day at $2.82. Its performance over the last five days remained 3.53%, which stands at -6.98% for a month. Going back further than one month, the 1-year performance after the recent close was -9.85%.